Determination of ER in ovarian cancer using monoclonal antibody technology
Nardelli, G.B.; Lamaina, V.; Dal Pozzo, M.; Onnis, G.L.
Clinical and Experimental Obstetrics and Gynecology 14(3-4): 185-187
1987
ISSN/ISBN: 0390-6663 PMID: 3331582 Document Number: 299890
The Monoclonal Antibody technology has been used in 29 cases of ovarian cancer. The immuno-enzyme-assay detected positive levels of estrogen cytoplasmatic receptor in 51.8% of the cases as well as in the nuclear (51.8%). Moreover, the ER/EIA technique screened positive levels of Total ER (ER/t) in 72.4% versus 65.5% obtained by DCC-method. 24.1% of the cases had negative ER/t levels observed by EIA. The monoclonal antibody anti-ER is a very interesting method for studying hormone-dependent tissue, because it uses an immunological binding to antigenic protein (receptor).